Safety Study of Mesenchymal Stem Cells and Spinal Fusion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

69 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-19

Study Completion Date

2019-10-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present prospective, randomized study, compares the spinal fusion obtained after instrumentation and the use of a biologic product (patient's mesenchymal cells obtained from his/her own bone marrow which will be fixed in human bone tissue form a donor), with the current procedure that consists in instrumented spinal fusion and the use of each patient's bone obtained from his/her iliac crest.

The working hypothesis proposes that the tissue engineering is a valid and useful technique to achieve bone regeneration, avoiding the need for obtaining patient's iliac crest and its associated morbidity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease

NCT03827096

Degenerative Disc Disease

TERMINATED PHASE1/PHASE2

Clinical Trial Based on the Use of Mesenchymal Stem Cells From Autologous Bone Marrow in Patients With Lumbar Intervertebral Degenerative Disc Disease

NCT01513694

Intervertebral Disc Disease

COMPLETED PHASE1/PHASE2

Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)

NCT01860417

Degenerative Disc Disease Intervertebral Disc Disease Low Back Pain

COMPLETED PHASE1/PHASE2

Collecting Bone Graft During Spinal Decompression and Posterolateral Lumbar Fusion to Better Define Bone Making Cells

NCT01409954

Pseudarthrosis After Fusion or Arthrodesis

ENROLLING_BY_INVITATION

Pivotal Study of rhBMP-2/ACS/Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease

NCT01494493

Degenerative Disc Disease

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prospective, open-label, randomized, parallel, single-dose phase I-II clinical trial in which 62 patients affected with L4-L5 degenerative spondylolisthesis grade I-II according to Meyerding and/or with L4-L5 degenerative discopathy needing spinal fusion will enter the trial with the primary objective of assessing the feasibility and safety of "ex-vivo" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion. Secondary objectives are to assess the efficacy of the implantation by imaging (computerized helicoidal tomography and X-ray) and clinical questionnaires (pain by visual analogue scale, quality of life by SF-36 and Oswestry Disability Index).

Patients will be randomized to one of the two treatment arms (instrumented spinal fusion and the tissue engineering product composed by "ex-vivo" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion or the standard treatment of instrumented spinal fusion and patient's bone iliac crest). Thereafter, patients will be followed for 12 months.

Imaging assessment will be done by an independent blinded radiologist.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lumbar Spondylolisthesis Involving L4-L5, and/or Degenerative Discopathy Involving L4-L5

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

XCEL-MT-OSTEO-ALPHA

"ex-vivo" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue for spinal fusion

Group Type EXPERIMENTAL

XCEL-MT-OSTEO-ALPHA

Intervention Type BIOLOGICAL

Isolation and "ex-vivo" expansion of mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia, División de Terapias Avanzadas delBanc de Sang i Teixits. After expansion, MSCs are fixed in allogenic bone tissue and implanted in instrumented spinal fusion.

Standard treatment

Instrumented spinal fusion together with patient's bone iliac crest.

Group Type SHAM_COMPARATOR

Standard treatment

Intervention Type PROCEDURE

Instrumented spinal fusion together with patient's bone iliac crest

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

XCEL-MT-OSTEO-ALPHA

Isolation and "ex-vivo" expansion of mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia, División de Terapias Avanzadas delBanc de Sang i Teixits. After expansion, MSCs are fixed in allogenic bone tissue and implanted in instrumented spinal fusion.

Intervention Type BIOLOGICAL

Standard treatment

Instrumented spinal fusion together with patient's bone iliac crest

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* L4-L5 degenerative spondylolisthesis grade I-II Meyerding isolated or associated to more than one level, and/or L4-L5 degenerative discopathy isolated or associated to more than one level.
* 18 to 85 years of age (male and female)
* Informed Consent Form signed
* The patient is able to understand the nature of the study

Exclusion Criteria

* Previous spine surgery
* L4 isthmic spondylolisthesis
* Smoker (more than 10 cigarettes a day)
* Systemic or local infection
* Patients treated with steroids (oral or systemic) within 3 months of entering the study, or treated with biphosphonates for more than 10 years
* Positive serology for HIV-1 or HIV-2, Hepatitis B (HBsAg), Hepatitis C (Anti-HCV-Ab) or Syphilis.
* Pregnant woman or intended to become pregnant, or breath feeding
* Neoplasia within the previous 5 years, or without remission
* Immunosuppressive states (except diabetes mellitus. Treatment with therapies is allowed)
* Significant abnormal laboratory tests that contraindicates the surgery.
* Participation in another clinical trial or treated with an investigational medicinal product the previous 3 months
* Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria
* The patient does not accept to be followed-up for a period that could exceed the clinical trial length
* The patient is legally dependent

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No